Latest Healthcare News

INOVIQ Limited has raised $11.5 million through a $9.5 million placement and a $2 million share purchase plan to accelerate the development and commercialisation of its EXO-OC ovarian cancer test and exosome therapeutic program.

Immuron Limited reports a robust 34% year-on-year sales increase for Q1 FY26, driven by strong growth in Australia and the USA, while Canadian sales dip seasonally. The company’s marketing efforts and expanding retail presence underpin this momentum.

PainChek Limited has secured its first US customer, Jewish Home Family, just days after receiving FDA De Novo clearance for its AI-powered pain assessment app, marking a significant step into the $100 million US aged care market.

Artrya Limited has successfully navigated a key FDA Q-Submission meeting, receiving clear guidance on the regulatory pathway for its Salix Coronary Flow module, with a 510(k) submission planned by year-end.

Pacific Smiles Group Limited has issued a Target’s Statement endorsing Beam Dental Bidco’s $2.20 per share off-market takeover bid. The Independent Expert deems the offer fair and reasonable, and the Independent Board Committee urges shareholders to accept, barring a superior proposal.

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.

Orthocell Limited has reported a record $3 million quarterly revenue, driven by strong sales of its nerve repair product Remplir in Australia and Singapore, while advancing its rollout in the US and Canada ahead of schedule.

Beam Dental Bidco Pty Ltd has launched an unconditional $2.20 per share takeover bid for Pacific Smiles Group Limited, offering a 37.5% premium and aiming to consolidate full ownership. The offer is unanimously recommended by Pacific Smiles’ Independent Board Committee, with plans to delist the company from the ASX upon success.

Pacific Smiles Group has agreed to an unconditional $2.20 per share cash takeover offer from its majority shareholder Genesis Bidco, representing a 37.5% premium. The Independent Board Committee recommends shareholders accept the offer, pending no superior proposal and ongoing fairness confirmation.

MedAdvisor Limited will have its trading suspension lifted on 10 October 2025 following the lodgement of its annual financial report, marking a key moment for investors.

Pathkey.AI’s TrialKey platform continues to validate its AI-driven clinical trial success predictions, with September 2025 seeing an average 43.6% share price increase across flagged biotech stocks.